XWELL, Inc. — Form 8-K Summary
Filing date: October 8, 2026. This current report concerns a subsidiary share repurchase in preparation for a proposed sale; it does not report a quarterly or annual operating period.
Business context and transaction
XpresTest, Inc., a wholly owned subsidiary of XWELL, repurchased 279.5 shares of its common stock, previously issued as restricted stock awards, for approximately $2.7 million in cash, or $9,634.09 per share. The repurchase fully vested any awards that had not previously vested. No XpresTest RSAs remain outstanding, and XWELL owns all issued and outstanding XpresTest shares.
The repurchase is related to the proposed sale announced July 6, 2026. Under the purchase agreement, XWELL plans to sell its equity interests in both XpresTest and XpresSpa to Express Wellness Group, LLC. The filing does not state that the sale has closed.
Key financial and transaction metrics
| Item | Reported amount or detail |
|---|---|
| Total repurchase | Approximately $2.7 million for 279.5 shares |
| Price per share | $9,634.09 |
| Director and executive purchases | Bruce T. Bernstein: 107 shares for $1,030,847.61; Ezra T. Ernst: 55 shares for $529,874.94; Ian Brown: 10 shares for $96,340.90, including five that vested in connection with the repurchase |
| Other holders | 107.5 shares held by five other current or former employees and service providers |
The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity metrics, and no clear value for the proposed sale’s total purchase price.
Material changes and sale-expense treatment
The $9,634.09 per-share price matches the price agreed by XWELL and the buyer for the awards under the purchase agreement. The repurchase was completed early with the buyer’s consent to simplify XpresTest’s capitalization ahead of the proposed sale. The amounts would have been treated as XWELL sale expenses and reduced the buyer’s purchase price dollar-for-dollar if paid at closing. Because they have been paid, they will not be included in the calculation of unpaid sale expenses under the agreement.
The filing does not provide comparable-period operating results or quantify any broader effect on XWELL’s financial position.
Outlook, risks, and items to verify
The proposed sale remains subject to the purchase agreement’s terms and conditions. XWELL says stockholders will be asked at a special meeting to vote on, among other matters, approval and adoption of the agreement. The filing cautions that forward-looking statements are subject to risks and uncertainties described more fully in the preliminary proxy statement; it gives no sale-closing date or updated transaction guidance.
- Verify whether XWELL stockholders approve the proposed sale and whether all closing conditions are satisfied.
- Review the definitive proxy statement and transaction documents for the sale consideration, adjustments, and other terms; this filing does not state the total purchase price.
- Confirm the final treatment of sale expenses and whether the proposed sale closes.
- Review the filed stock repurchase agreement and side letter for the detailed terms of the RSA repurchases.